Quarterly ResultAug 13, 2026, 08:56 AM
Dogwood Therapeutics Q2 Net Loss $11.5M; Halneuron® Phase 2b on track
AI Summary
Dogwood Therapeutics reported a net loss of $11.5 million, or $0.34 per share, for the second quarter ended June 30, 2026. The company recognized a significant non-cash IPR&D impairment charge of $9.2 million. Despite the loss, Dogwood provided positive updates on its clinical pipeline, including the Halneuron® Phase 2b trial for Chemotherapy Induced Neuropathy being on track for top-line results in fall 2026, and the commencement of a long-term extension study. Additionally, the company announced a worldwide development and commercialization partnership for legacy antiviral assets with a potential value of up to $100 million.
Key Highlights
- Q2 2026 net loss attributable to common stockholders was $11.5 million, or $0.34 per share.
- Cash on hand was $9.6 million as of June 30, 2026, providing runway through Q4 2026.
- Recognized a $9.2 million non-cash IPR&D impairment charge in Q2 2026.
- Halneuron® Phase 2b trial for CINP has 217 patients enrolled; top-line results expected fall 2026.
- Commenced Phase 2b Long-Term Extension Study for Halneuron®.
- Announced worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100 million.
- Research and development expenses increased to $3.2 million in Q2 2026 from $2.6 million in Q2 2025.
- General and administrative expenses increased to $1.6 million in Q2 2026 from $1.3 million in Q2 2025.
Price Impact
More from DWTX